Clinical Trial Update: Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating eribulin in combination with an anti-PD-1 antibody in metastatic triple-negative breast cancer (TNBC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Anti-PD-1 antibody
• Eribulin (eribulin mesilate)

Snippet

Sponsor: Beijing 302 Hospital | Conditions: TNBC - Triple-Negative Breast Cancer | Phase 2 | Status: UNKNOWN